Want to see IN:KIMS full AI Analyst Report?
KIMS Stock Chart & Stats
₹653.00
₹11.55(1.78%)
At close: 4:00 PM EST
₹653.00
₹11.55(1.78%)
Day’s Range― - ―
52-Week Range₹575.55 - ₹858.15
Previous CloseN/A
Volume1.26M
Average Volume (3M)23.04K
Market Cap
₹337.03B
Enterprise Value₹293.76K
Total Cash (Recent Filing)₹1.74B
Total Debt (Recent Filing)₹31.87B
Price to Earnings (P/E)131.0
Beta0.76
Next Earnings
Aug 12, 2026EPS Estimate
1.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.39
Shares Outstanding420,006,470
10 Day Avg. Volume26,167
30 Day Avg. Volume23,042
Financial Highlights & Ratios
PEG Ratio-2.77
Price to Book (P/B)11.07
Price to Sales (P/S)6.37
P/FCF Ratio-22.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.02
Revenue Forecast (FY)₹51.23B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue ExpansionSustained 3x revenue growth over 2021–2026 indicates durable demand for KIMS' services and successful capacity scaling. Long-term top-line momentum supports leverage for network investment, specialist recruiting, and negotiating power with payers, underpinning future profit potential if efficiencies follow.
Integrated Multi-specialty NetworkAn integrated multi-specialty hospital network delivers diversified inpatient/outpatient, diagnostics and pharmacy revenue streams, raises patient retention and referral advantages, and builds scale in tertiary/quaternary care. These structural attributes create durable competitive barriers and recurring revenue.
Ongoing Mid‑teens Growth In 2026Continued mid‑teens revenue growth in 2026 shows the business retains organic demand and pricing/volume momentum despite expansion. Persistent top-line growth can improve utilization and fixed-cost absorption over time, supporting margin recovery if cost discipline and mix improve.
Bears Say
Sharply Rising LeverageRapid increase in debt-to-equity materially raises financial risk and reduces strategic flexibility. Higher leverage elevates interest expense and refinancing sensitivity, constrains ability to fund operations or acquisitions internally, and amplifies downside if margins or cash flow weaken.
Deeply Negative Free Cash FlowPersistent and large negative free cash flow suggests heavy capex/reinvestment and weak cash conversion of earnings. This forces reliance on external financing, heightens liquidity and execution risk, and limits ability to deleverage or return capital until cash generation normalizes.
Margin Compression & Earnings DeclineSignificant deterioration in gross and net margins alongside EPS contraction indicates cost pressures, adverse mix, or weaker realizations. Lower profitability reduces internal cash generation, weakens ROE, and makes the firm more vulnerable to higher financing costs amid rising leverage.
Krishna Institute of Medical Sciences Limited News
KIMS FAQ
What was Krishna Institute of Medical Sciences Limited’s price range in the past 12 months?
Krishna Institute of Medical Sciences Limited lowest stock price was ₹575.55 and its highest was ₹858.15 in the past 12 months.
What is Krishna Institute of Medical Sciences Limited’s market cap?
Krishna Institute of Medical Sciences Limited’s market cap is ₹337.03B.
When is Krishna Institute of Medical Sciences Limited’s upcoming earnings report date?
Krishna Institute of Medical Sciences Limited’s upcoming earnings report date is Aug 12, 2026 which is in 22 days.
How were Krishna Institute of Medical Sciences Limited’s earnings last quarter?
Krishna Institute of Medical Sciences Limited released its earnings results on May 15, 2026. The company reported ₹1.2 earnings per share for the quarter, missing the consensus estimate of ₹1.528 by -₹0.328.
Is Krishna Institute of Medical Sciences Limited overvalued?
According to Wall Street analysts Krishna Institute of Medical Sciences Limited’s price is currently Overvalued.
Does Krishna Institute of Medical Sciences Limited pay dividends?
Krishna Institute of Medical Sciences Limited does not currently pay dividends.
What is Krishna Institute of Medical Sciences Limited’s EPS estimate?
Krishna Institute of Medical Sciences Limited’s EPS estimate is 1.48.
How many shares outstanding does Krishna Institute of Medical Sciences Limited have?
Krishna Institute of Medical Sciences Limited has 420,006,470 shares outstanding.
What happened to Krishna Institute of Medical Sciences Limited’s price movement after its last earnings report?
Krishna Institute of Medical Sciences Limited reported an EPS of ₹1.2 in its last earnings report, missing expectations of ₹1.528. Following the earnings report the stock price went down -1.767%.
Which hedge fund is a major shareholder of Krishna Institute of Medical Sciences Limited?
Currently, no hedge funds are holding shares in IN:KIMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Krishna Institute of Medical Sciences Limited
Krishna Institute of Medical Sciences Limited, known by its brand KIMS Hospitals across India, delivers a broad spectrum of medical and healthcare services. The institution boasts a comprehensive array of specialized fields, including cardiology, dentistry, neurology, oncology, orthopedics, nephrology, reproductive medicine, and robotic surgeries. Additionally, it offers expertise in gastroenterology, hepatology, heart and lung transplantation, general organ transplantation, maternal and pediatric care. Other key areas of focus include emergency and accident services, biochemistry, anesthesiology, bariatric surgery, andrology and infertility treatments, arthroscopy, Alzheimer's care, and dedicated bone and joint centers. Founded in 1973, the company is headquartered in Secunderabad, India.
Technical Analysis
Apollo Hospitals Enterprise Limited
―
Fortis Healthcare Ltd.
―
Max Healthcare Institute Ltd
―
Global Health Limited
―
Narayana Hrudayalaya Ltd.
―